Precision Medicine in Oncology®

Ten or 15 years ago, a diagnosis of advanced non– small cell lung cancer (NSCLC) led directly to a discussion of chemotherapy.

Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference.

"Precision, personalized, individualized, targeted" - most oncologists are well acquainted with these terms. On Tuesday, President Obama introduced this concept to the nation in his State of the Union Address.

The New York State Stem Cell Science Program recently awarded a 4-year $11.9 million grant to Roswell Park Cancer Institute to fund research and development of a stem-cell based treatment for ovarian cancer.

Andre Goy, MD, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, sat down with OncLive to discuss the recent merger and what that means for the future of precision medicine.

Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche's recent acquisition of the molecular testing company Foundation Medicine.

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.

Roche has acquired a majority stake in the molecular testing company Foundation Medicine for $1.03 billion, launching a partnership that will focus on the development of personalized medicine for patients with cancer.

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

A lung cancer researcher who has served on the editorial boards of major medical journals, Howard L. "Jack" West, MD, has made communicating with oncology specialists and patients a part of his professional mission.

A biomarker has been found that may help determine which Gleason 7 (GS7) cancers are particularly aggressive.

Rituximab dose should be based on age and sex.

Drugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.